UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
April 16, 2004
---------------------------
(Date of Report)
ELITE PHARMACEUTICALS, INC.
-----------------------------
(Exact name of registrant as specified in its charter)
Delaware 333-45241 22-3542636
------------ ------------- --------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
165 Ludlow Avenue, Northvale, New Jersey 07647
------------------------------------------------
(Address of principal executive offices)
(201) 750-2646
----------------
(Registrant's telephone number, including area code)
Item 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
The date of the annual stockholders meeting of the Registrant which was
tentatively scheduled to be held on Monday, April 19, 2004 has been postponed.
The Registrant will notify the stockholders once a new date has been finalized.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: April 16, 2004
ELITE PHARMACEUTICALS, INC.
By: /s/ John A. Moore
--------------------------
Name: John A. Moore
Title: Chairman